HomeADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
Nakaraang pagsara
$0.62
Sakop ng araw
$0.57 - $0.63
Sakop ng taon
$0.53 - $2.05
Market cap
158.62M USD
Average na Volume
2.43M
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 40.90M | 458.83% |
Gastos sa pagpapatakbo | 21.28M | 31.63% |
Net na kita | -17.62M | 61.37% |
Net profit margin | -43.07 | 93.09% |
Kita sa bawat share | -0.01 | 70.15% |
EBITDA | -11.86M | 72.88% |
Aktuwal na % ng binabayarang buwis | -4.95% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 186.09M | 15.06% |
Kabuuang asset | 317.44M | 7.01% |
Kabuuang sagutin | 237.45M | 13.88% |
Kabuuang equity | 79.99M | — |
Natitirang share | 255.88M | — |
Presyo para makapag-book | 2.00 | — |
Return on assets | -11.48% | — |
Return on capital | -24.62% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -17.62M | 61.37% |
Cash mula sa mga operasyon | -54.45M | -20.58% |
Cash mula sa pag-invest | -66.02M | -215.20% |
Cash mula sa financing | 25.00M | 4,094.80% |
Net change in cash | -95.25M | -840.01% |
Malayang cash flow | -41.07M | -62.70% |
Tungkol
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Itinatag
2008
Website
Mga Empleyado
449
